USPTO Examiner STOICA ELLY GERALD - Art Unit 1647

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19067809Nectin-4 binding miniproteins, conjugates and methods of use thereofFebruary 2025July 2025Allow410NoNo
19019930GAMMA DELTA T CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS, AND PRODUCTION METHOD THEREFORJanuary 2025August 2025Allow710YesNo
18901784DENDRITIC CELL PREPARATION AND PREPARATION METHOD THEREOFSeptember 2024July 2025Allow920NoNo
18203132LIPIDOMICS-BASED IDENTIFICATION OF PANCREATIC CANCER PATIENTSMay 2023February 2026Allow3300NoNo
18319901METHOD FOR CULTURING TUMOR INFILTRATING LYMPHOCYTESMay 2023June 2024Allow1321YesNo
18314205IgG Fc-IL2-Ralpha-IL2 fusions and methods of use thereofMay 2023January 2024Allow921YesNo
18314576DEVICES AND METHODS FOR ISOLATING TUMOR INFILTRATING LYMPHOCYTES AND USES THEREOFMay 2023January 2025Abandon2020NoNo
18298542NOVEL IL2 AGONISTS AND METHODS OF USE THEREOFApril 2023January 2025Abandon2111NoNo
18188991ANTIBODY-DRUG CONJUGATES THROUGH SPECIFIC LINKER OLIGOPEPTIDESMarch 2023January 2024Allow1011NoNo
18186901MODIFICATION OF CAR-T CELLSMarch 2023February 2024Allow1121NoNo
18176934PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING AN IMMUNE CHECKPOINT INHIBITOR ANTIBODY AND A FUSION PROTEIN COMPRISING AN IL-2 MUTANT AND A CD80 EXTRACELLULAR DOMAINMarch 2023March 2026Allow3710NoNo
18089754Masked IL-2-Fc fusion polypeptidesDecember 2022October 2023Allow1010NoNo
18088400METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS, ANDROGEN DEPRIVATION THERAPY AND ANTI-ANDROGEN RECEPTOR THERAPYDecember 2022February 2026Allow3830NoNo
18069511Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for CancerDecember 2022December 2025Abandon3610NoNo
18068694METHODS OF TREATING BLEEDING DISORDERS BY ADMINISTRATION OF CHIMERAS COMPRISING ANTI-VON WILLEBRAND FACTOR ANTIBODIES AND CLOTTING FACTORSDecember 2022October 2025Allow3410NoNo
18064793TREATMENT OF CANCER WITH IMMUNE STIMULATORSDecember 2022October 2025Allow3511NoNo
18008877LIPID NANOPARTICLES COMPRISING STEROLS AND mRNADecember 2022March 2026Allow3910NoNo
18062146INTRATUMORAL VACCINATIONDecember 2022December 2025Abandon3610NoNo
18000153METHOD OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROMENovember 2022January 2026Allow3810NoNo
18057591AGNOSTIC ANTI-MULLERIAN HORMONE RECEPTOR BINDING PEPTIDESNovember 2022February 2026Allow3911NoNo
18057465POLYNUCLEOTIDES ENCODING ANTI-PD-L1 ANTIBODIESNovember 2022January 2026Allow3810NoNo
17922882METHOD OF TREATMENT OF SOFT TISSUE SARCOMA WITH A PEPTIDE COMRPISING A PCNA INTERACTING MOTIFNovember 2022November 2025Allow3610NoNo
18050485METHOD OF KILLING LEUKEMIA CELLS BY ADMINISTRATION OF RECOMBINANT Y3 PROTEINSOctober 2022December 2025Allow3720NoNo
17921577MITOCHONDRIAL-DERIVED PEPTIDES AND ANALOGS THEREOF FOR USE AS A THERAPY FOR AGE-RELATED DISEASES INCLUDING CANCEROctober 2022January 2026Allow3911NoNo
17920174Manufacturing Process for Heterodimeric IL-12 p35-Fc and p40-FC-Fusion ProteinsOctober 2022July 2025Allow3300NoNo
17968611TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING NKG2D ANTIGEN BINDING DOMAINSOctober 2022June 2025Allow3210NoNo
17918175INTERFERON TAU AS ANTIVIRAL THERAPYOctober 2022January 2026Abandon3901NoNo
17995780INDIVIDUALIZED THERAPEUTIC ANTICANCER VACCINEOctober 2022March 2026Allow4111NoNo
17962413CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOFOctober 2022October 2025Allow3610NoNo
17938447DELIVERY SYSTEM FOR TARGETED DELIVERY OF A THERAPEUTICALLY ACTIVE PAYLOADOctober 2022October 2025Abandon3611NoNo
17938109PD-1 AND PD-L1 BINDING AGENTSOctober 2022March 2025Allow2911NoNo
17938092Conjugated Fibronectin-Binding Peptides for Use in Tumor or Fibrosis Diagnosis and TherapyOctober 2022October 2025Allow3710NoNo
17907013COMPOSITIONS COMPRISING NON-IMMUNOGENIC RNA ENCODING IMMUNOGENIC EPITOPES AND INTERFERON ALPHASeptember 2022March 2026Allow4211NoNo
17934113Agents and Methods for the Prevention or Treatment of H. Pylori InfectionsSeptember 2022August 2025Allow3511NoNo
17911891PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING FUSION PROTEIN INCLUDING IL-2 PROTEIN AND CD80 PROTEIN AND ANTICANCER DRUGSeptember 2022September 2023Allow1210YesNo
17911816COMBINATION TREATMENT FOR CANCERSeptember 2022January 2026Abandon4010NoNo
17906199NEW THERAPEUTIC USE OF ANAKINRA FOR COVID-19September 2022January 2026Abandon4010NoNo
17944066Method of treatment of colorectal, breast and lung cancer with metal containing immune agonist complexesSeptember 2022September 2025Allow3611NoNo
17910532MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCERSeptember 2022March 2026Allow4211YesNo
17930526P53, P63, AND P73 HOMO-TETRAMERIC COMPOSITIONSSeptember 2022June 2024Allow2121NoNo
17930555METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIESSeptember 2022December 2025Abandon4001NoNo
17930542METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIESSeptember 2022December 2025Abandon4010NoNo
17902240NON-ADULT HUMAN DOSING OF ANTI-CD30 ANTIBODY-DRUG CONJUGATES FOR TREATMENT OF HEMATOLOGICAL OR LYMPHOID CANCERSeptember 2022January 2025Allow2900NoNo
17908381ANTI-EGFR ANTIBODY-DRUG CONJUGATE WITH A CYCLIC DINUCLEOTIDE DERIVATIVEAugust 2022February 2026Allow4111NoNo
17823356COMPLEXES BETWEEN CD40 AND COMPOUNDS COMPRISING BENZIMIDAZOLE MOIETIESAugust 2022August 2025Allow3521NoNo
17898317METHOD FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER COMPRISING CFLIP SIRNAAugust 2022April 2025Allow3210NoNo
17893698OXABICYCLOHEPTANES FOR TREATMENT OF SMALL CELL LUNG CANCERAugust 2022December 2025Abandon4010NoNo
17821459TARGETED DELIVERY OF ANTI-CSF1R ANTIBODIES TO JOINTS WITH TENOSYNOVIAL GIANT CELL TUMORSAugust 2022April 2023Allow810NoNo
17820794METHOD OF TREATING SOLID CANCERS WITH BISPECIFIC INTERLEUKIN-ANTI-TCRß MOLECULESAugust 2022January 2024Allow1731YesNo
17820217EXTENDED LOCAL RELEASE OF anti-CSFR1 ANTIBODIESAugust 2022April 2025Allow3210NoNo
17819911RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPYAugust 2022June 2025Abandon3410NoNo
17878221NEUREGULIN FOR THE TREATMENT AND/OR PREVENTION OF TUMORS OF THE NERVOUS SYSTEMAugust 2022June 2025Abandon3410NoNo
17877198METHOD OF STIMULATING NEUTROPHIL SURVIVAL AND REDUCING NEUTROPENIAJuly 2022May 2025Allow3310NoNo
17759538METHODS OF TREATING AN INFLAMMATORY OR OBSTRUCTIVE AIRWAY DISEASE USING ANTI-TSLP ANTIBODYJuly 2022December 2025Abandon4101NoNo
17795814COMBINATION THERAPY FOR TREATMENT OF CANCER AND CANCER METASTASISJuly 2022December 2025Abandon4101NoNo
17815056METHODS FOR TREATMENT OF CANCERS HARBORING AN H3K27M MUTATIONJuly 2022December 2025Allow4011YesNo
17815086IMMUNOGENIC COMPOSITIONS COMPRISING NUCLEIC ACIDS FOR RAS PEPTIDES AND THEIR USE FOR TREATING CANCERJuly 2022March 2025Allow3210NoNo
17862952SELF-ASSEMBLING SYNTHETIC PROTEINS COMPRISING CHOLERA TOXIN BETA SUBUNITJuly 2022June 2025Allow3510NoNo
17830381HUMANIZED ANTI-HUMAN-PD-1 ANTIBODY AND METHODS OF USING THEM FOR CANCER TREATMENTJune 2022February 2025Allow3310NoNo
17780396PHARMACEUTICAL COMPOSITIONMay 2022November 2025Abandon4210NoNo
17780364PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING AN IMMUNE CHECKPOINT INHIBITOR ANTIBODY AND A FUSION PROTEIN COMPRISING AN IL-2 MUTANT AND A CD80 EXTRACELLULAR DOMAINMay 2022January 2023Allow700NoNo
17640516METHOD FOR ACQUIRING DATA FOR DISTINGUISHING PRESENCE OF CANCER CELLS AND/OR DISTINGUISHING ANTICANCER DRUG RESISTANCE, METHOD FOR ACQUIRING PREDICTION DATA, USE OF DISTINCTION MARKER IN SAME, AND DISTINGUISHING KITMay 2022February 2026Abandon4711YesNo
17737159RECOMBINANT PROTEIN TARGETING PD-L1 AND VEGF AND COMPOSITIONS THEREOF.May 2022September 2025Allow4120YesNo
17736431FUSION POLYPEPTIDES COMPRISING INTERLEUKIN 12 AND A METAL-HYDROXIDE BINDING POLYPEPTIDEMay 2022September 2025Allow4001YesNo
17734694Antigenic Peptides For Treatment Of B-Cell MalignancyMay 2022May 2023Allow1312NoNo
17730261METHODS OF BOOSTING THYMIC REGENERATION IN PATIENTS SUFFERING FROM A THYMIC INJURY BY USING RANKLApril 2022May 2025Abandon3710NoNo
17716873MASKED INTERLEUKIN-12 POLYPEPTIDESApril 2022April 2023Allow1220YesNo
17711849METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN TREATING CANCERApril 2022May 2024Allow2531NoNo
17709706NOVEL IL2 AGONISTS AND METHODS OF USE THEREOFMarch 2022February 2023Allow1121YesNo
17699846PROPROTEINS AND METHODS OF USE THEREOFMarch 2022September 2025Abandon4211NoNo
17698657BISPECIFIC ANTIBODIES TO ROR1 AND CD3March 2022May 2025Abandon3710NoNo
17696269CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USEMarch 2022March 2025Allow3610NoNo
17696222MASKED ACTIVATABLE INTERFERON CONSTRUCTSMarch 2022February 2023Allow1112YesNo
17693017MESOPOROUS SILICA COMPOSITIONS COMPRISING INFLAMMATORY CYTOKINES FOR MODULATING IMMUNE RESPONSESMarch 2022April 2025Abandon3701NoNo
17679545ANTIBODIES AGAINST IGFR-LIKE RECEPTOR AND USES THEREOFFebruary 2022December 2025Allow4520NoNo
17631161METHODS FOR TREATING OR PREVENTING CANCERS INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTSJanuary 2022March 2026Allow5011NoNo
17571398EXTENDED LOCAL RELEASE OF ANTI-CSFR1 ANTIBODIESJanuary 2022May 2022Allow511YesNo
17625076ANTIBODIES AGAINST TAU EPITOPESJanuary 2022September 2025Allow4511NoNo
17622467HYDROPHILIC LINKERS FOR MULTIVALENT PEPTIDE CONJUGATESDecember 2021March 2026Allow5111NoNo
17622552NOVEL TUMOR-SPECIFIC ANTIGENS FOR OVARIAN CANCER AND USES THEREOFDecember 2021March 2026Allow5021NoNo
17559301NUCLEIC ACIDS ENCODING ANTI-IL1RAP ANTIBODIES AND THEIR USESDecember 2021March 2025Allow3811NoNo
17554423METHOD OF MAKING AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIESDecember 2021July 2025Allow4320NoNo
17551679IMMUNOGENIC COMPOSITIONS COMPRISING NUCLEIC ACIDS FOR RAS PEPTIDESDecember 2021April 2022Allow411NoNo
17551412LIGAND-TARGETED CELL CONJUGATE (LTCC)-BASED ANTI-TUMOR IMMUNE CELLDecember 2021April 2025Allow4011NoNo
17551908Methods of treating IL1RAP associated cancers with Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) AntibodiesDecember 2021April 2025Allow4011NoNo
17547034ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOFDecember 2021March 2025Abandon4001NoNo
17541765STABILIZED PROTEOLYTICALLY ACTIVATED GROWTH DIFFERENTIATION FACTOR 11December 2021March 2025Abandon3901NoNo
17540477COMBINATION IMMUNOTHERAPY FOR TREATMENT OF MELANOMA, COLON OR NON-SMALL CELL LUNG CANCERSDecember 2021January 2025Allow3810NoNo
17536974ANTI-CD40 BINDING MOLECULES HAVING ENGINEERED FC DOMAINS AND THERAPEUTIC USES THEREOFNovember 2021April 2025Abandon4110NoNo
17533945METHODS OF USE FOR ANTI- ILT2 ANTIBODIESNovember 2021April 2025Allow4021NoNo
17456205ANTI-MULLERIAN HORMONE RECEPTOR BINDING PEPTIDESNovember 2021August 2022Allow920NoNo
17611046METHOD FOR PREPARING IMMUNE-TOLERIZED EXTRACELLULAR VESICLE CONTAINING LACTATE DEHYDROGENASE B AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA, AND COMPOSITION COMPRISING THE EXTRACELLULAR VESICLENovember 2021May 2023Allow1800NoNo
17520399METHODS AND COMPOSITIONS FOR TREATING ALLERGIC OCULAR DISEASESNovember 2021March 2025Abandon4101NoNo
17519606HIGH CONCENTRATION ANTI-BLYS PHARMACEUTICAL FORMULATIONSNovember 2021January 2025Allow3810NoNo
17453736LYMPHANGIOGENESIS FOR THERAPEUTIC IMMUNOMODULATIONNovember 2021March 2026Abandon5221NoNo
17519082Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 alleleNovember 2021July 2025Allow4420NoNo
17506483Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereofOctober 2021September 2023Allow2311NoNo
17451176VARIANT SURVIVIN VACCINE FOR TREATMENT OF MYELOMAOctober 2021February 2025Allow4010NoNo
17500616ANTIBODY EPITOPEOctober 2021August 2025Abandon4620NoNo
17487409METHOD FOR INHIBITING PLATELET DERIVED GROWTH FACTOR SIGNALING WITH C3aR OR C5aR ANTIBODIESSeptember 2021May 2025Abandon4411NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STOICA, ELLY GERALD.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
4
(66.7%)
Examiner Reversed
2
(33.3%)
Reversal Percentile
49.3%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
68
Allowed After Appeal Filing
19
(27.9%)
Not Allowed After Appeal Filing
49
(72.1%)
Filing Benefit Percentile
41.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 27.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner STOICA, ELLY GERALD - Prosecution Strategy Guide

Executive Summary

Examiner STOICA, ELLY GERALD works in Art Unit 1647 and has examined 1,331 patent applications in our dataset. With an allowance rate of 63.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.

Allowance Patterns

Examiner STOICA, ELLY GERALD's allowance rate of 63.5% places them in the 24% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by STOICA, ELLY GERALD receive 1.71 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by STOICA, ELLY GERALD is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +26.3% benefit to allowance rate for applications examined by STOICA, ELLY GERALD. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.5% of applications are subsequently allowed. This success rate is in the 52% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 59.6% of cases where such amendments are filed. This entry rate is in the 85% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 120.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 82% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 86.4% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 73.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 58.3% are granted (fully or in part). This grant rate is in the 61% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.4% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.2% of allowed cases (in the 52% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.